 SAN DIEGO, June 17, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that TPX-0022, the companys inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R, has been granted orphan drug designation by the Food and Drug Administration FDA for the treatment of patients with gastric cancer, including gastroesophageal junction adenocarcinoma. 